EUCTR2016-002971-91-GR进行中（未招募）1 期
A randomized, double-masked, placebo-controlled exploratorystudy to evaluate safety, tolerability, pharmacodynamics andpharmacokinetics of orally administered BI 1467335 for 12weeks with a 12 week follow up period in patients with nonproliferativediabetic retinopathy without center-involveddiabetic macular edema
Boehringer Ingelheim Ellas SA0 个研究点目标入组 100 人开始时间: 2017年9月28日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Of full age (according to local legislation, usually = 18 years) and = 80 years at screening
- •2. Male or female patients. Women of childbearing potential (WOCBP)1 must be ready and
- •able to use two methods of contraception with at least one of them being a highly
- •effective method of birth control per ICH M3 (R2) that result in a low failure rate of less
- •than 1% per year when used consistently and correctly. A list of contraception methods
- •meeting these criteria is provided in the patient information.
- •3. Diagnosis of diabetes mellitus (type 1 or type 2):
- •- Documented diabetes by American Diabetes Association (ADA) and/or World Health
- •Organization criteria
- •- Antidiabetic medication stable for =3 months prior to screening and expected to be
- •stable throughout the trial (no change in medication or the dose, except for insulin the
- •prescribed total daily dose change not more than 10%)
- •4. Glycosylated hemoglobin (HbA1c) = 10% at screening
- •5. Non-proliferative diabetic retinopathy (NPDR) without center-involved diabetic macular
- •edema (CI-DME) in the study eye at screening with NPDR level 47 or level 53, as
- •determined by the CRC by using the DR severity scale (DRSS)
- •6. Best corrected visual acuity ETDRS letter score = 70 letters in the study eye at screening
- •7. Media clarity, pupillary dilation and individual cooperation sufficient for adequate retinal
- •examination including fundus photographs and OCT
- •8. Signed and dated written informed consent in accordance with ICH-GCP and local
- •legislation prior to admission to the trial
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 80
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 20
排除标准
- •1. Additional eye disease in the study eye that, in the opinion of the investigator, could
- •compromise or alter visual acuity during the course of the study (e.g. vein occlusion,
- •uncontrolled intraocular pressure (IOP) >24 mmHg on optimal medical treatment,
- •glaucoma with visual field loss, uveitis or other ocular inflammatory disease,
- •vitreomacular traction, monocular vision, history of ischemic optic neuropathy, or genetic
- •disorders such as retinitis pigmentosa)
- •2. Active center-involved DME (CI-DME) on clinical examination and OCT central
- •subfield thickness above 300 µm in the study eye, as measured by Optovue OCT
- •3. Anterior segment and vitreous abnormalities in the study eye that would compromise the
- •adequate assessment of the best corrected visual acuity or an adequate examination of the
- •posterior pole
- •4. Evidence of neovascularization on clinical examination including active
- •neovascularization of the iris (small iris tufts are not an exclusion) or angle
- •neovascularization in the study eye, ruled out by gonioscopy (documented in the last 4
- •weeks before screening or performed at screening)
- •5. Prior pan-retinal photocoagulation (defined as = 100 burns placed previously outside of
- •the posterior pole) in the study eye
- •6. History of DME or DR treatment with macular laser within 3 months prior to screening,
- •or intraocular injections of medication within 6 months prior to screening, and no more
- •than 4 prior intraocular injections in the study eye at any time in the past
- •7. Patients treated with Monoamine Oxidase B (MAO-B) inhibitors (see Section 4.2.2.1) at
- •the time or up to 3 months prior to randomization or planned initiation during the trial
- •8. Current or planned, during the trial, use of medications known to be toxic to the retina,
- •lens or optic nerve, or cause vision loss
- •Further criteria apply.
研究者
相似试验
进行中（未招募）
1 期
Safety and effect on central retinal thickness of BI 1026706 in patients with diabetic macular edemaPatients with mild visual impairment due to center-involved diabetic macular edema (DME)MedDRA version: 18.1Level: LLTClassification code 10057934Term: Diabetic macular edemaSystem Organ Class: 100000004853EUCTR2015-003529-33-BESCS Boehringer Ingelheim Comm.V125
进行中（未招募）
1 期
A study that tests BI 1467335 in patients with diabetic eyedisease (diabetic retinopathy). It looks at the way BI 1467335 istaken up, the effects it has, and how well it is tolerated.diabetic retinopathyEUCTR2016-002971-91-ITBOEHRINGER-INGELHEIM ITALIA S.P.A.100
进行中（未招募）
1 期
Safety and effect on central retinal thickness of BI 1026706 in patients with diabetic macular edemaEUCTR2015-003529-33-ESBoehringer Ingelheim España, S.A.125
进行中（未招募）
1 期
Safety and effect on central retinal thickness of BI 1026706 in patients with diabetic macular edemaPatients with mild visual impairment due to center-involved diabetic macular edema (DME)MedDRA version: 19.1 Level: LLT Classification code 10057934 Term: Diabetic macular edema System Organ Class: 100000004853EUCTR2015-003529-33-PTnilfarma - União Internacional de Lab. Farmacêuticos, Lda169
进行中（未招募）
1 期
Safety and effect on central retinal thickness of BI 1026706 in patients with diabetic macular edemaPatients with mild visual impairment due to center-involved diabetic macular edema (DME)MedDRA version: 18.1Level: LLTClassification code 10057934Term: Diabetic macular edemaSystem Organ Class: 100000004853EUCTR2015-003529-33-HUBoehringer-Ingelheim RCV GmbH&Co KG125